Loading…
United Therapeutics Corporation is projected to rise to $612.10 by 2027, a +13% move from its current price of $541.58. UTHR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $535.48 | $541.71 | $548.02 | +0.02% |
| Jul 13 | $533.05 | $541.85 | $550.79 | +0.05% |
| Jul 14 | $531.22 | $541.98 | $552.95 | +0.07% |
| Jul 15 | $529.71 | $542.11 | $554.81 | +0.10% |
| Jul 16 | $528.40 | $542.25 | $556.46 | +0.12% |
| Jul 17 | $527.22 | $542.38 | $557.98 | +0.15% |
| Jul 18 | $526.16 | $542.52 | $559.38 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $526.16 | $542.52 | $559.38 | +0.17% |
| Week 2 | $520.42 | $543.45 | $567.50 | +0.35% |
| Week 3 | $516.27 | $544.39 | $574.04 | +0.52% |
| Week 4 | $512.94 | $545.33 | $579.77 | +0.69% |
| Week 5 | $510.12 | $546.28 | $584.99 | +0.87% |
| Week 6 | $507.68 | $547.22 | $589.84 | +1.04% |
| Week 7 | $505.51 | $548.16 | $594.42 | +1.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
United Therapeutics Corporation is a healthcare company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its portfolio includes Tyvaso DPI, Nebulized Tyvaso, Remodulin (treprostinil) injection, Orenitram, Adcirca, Unituxin, and Remunity Pump. It is also involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH; Nebulized Tyvaso for idiopathic pulmonary fibrosis; as well as xenografts, which are development-stage organ products, and preclinical products including EVLP/CLES.
The company also provides a range of development programs and collaborations in regenerative medicine and xenotransplantation. The company has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for subcutaneous delivery of treprostinil; MannKind Corporation to develop treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc.
to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation (UTHR) is a healthcare company with a current price of $536.59 and a market capitalization of $22.78B. It is ranked 548 by market size among listed assets. The long-range price outlook, as captured by the available forecast, shows meaningful upside over time, with the average price climbing from the 2026 baseline to substantially higher levels by 2050.
A major floor 11.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
The nearest ceiling, 4.1% above — a clean break opens room to run.
A major ceiling 10.2% above — clearing it would confirm fresh momentum.
Key UTHR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UTHR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $552.97 | Sell | $551.18 | Sell |
| MA 10 | $549.73 | Sell | $550.39 | Sell |
| MA 20 | $547.52 | Sell | $550.13 | Sell |
| MA 50 | $557.94 | Sell | $551.73 | Sell |
| MA 100 | $548.20 | Sell | $539.87 | Buy |
| MA 200 | $507.72 | Buy | $502.15 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.54 | Neutral |
| Stoch RSI (14) | 43.01 | Neutral |
| CCI (20) | -6.81 | Neutral |
| Williams %R (14) | -65.51 | Info |
| MACD (12,26,9) | 1.38 | Buy |
| ROC (12) | 0.50 | Buy |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 34.49 | Neutral |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | 2.19 | Buy |
| Ultimate (7,14,28) | 54.07 | Neutral |
| Momentum (10) | 3.67 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 554.85 | Sell |
| ADX (14) | 9.71 | Neutral |
| ATR (14) | 6.09 | Info |
The near-term technical picture for United Therapeutics is bullish, with sentiment recorded as BULLISH. The RSI(14) sits at 40, reflecting room to move higher on momentum. The chart shows a 50-day simple moving average of $565.40 and a 200-day simple moving average of $497.47, suggesting near-term support near the current price level and upside potential toward the resistance at $581.74.
The current price sits at $536.59 with a defined 30-day range between $495.37 and $581.24. The stock exhibits an annualized volatility of 20% over the period analyzed.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $464.93 | $541.58 | $685.59 | 0% | Neutral | |
| $501.30 | $612.10 | $781.43 | +13% | Neutral | |
| $539.75 | $671.43 | $880.34 | +24% | Bullish | |
| $613.11 | $774.46 | $1,037.04 | +43% | Bullish | |
| $696.43 | $891.58 | $1,215.37 | +65% | Bullish | |
| $812.00 | $1,052.23 | $1,457.03 | +94% | Bullish | |
| $896.25 | $1,174.53 | $1,649.51 | +117% | Bullish | |
| $879.17 | $1,164.28 | $1,656.29 | +115% | Bullish | |
| $945.87 | $1,265.07 | $1,821.17 | +134% | Bullish | |
| $1,031.94 | $1,393.24 | $2,028.01 | +157% | Bullish | |
| $1,544.26 | $2,174.58 | $3,317.09 | +302% | Bullish | |
| $2,972.47 | $4,489.17 | $7,340.26 | +729% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $464.93 | $541.58 | $654.63 | +0.00% |
| August 2026 | $481.05 | $563.16 | $673.63 | +3.99% |
| September 2026 | $470.88 | $553.90 | $667.69 | -1.65% |
| October 2026 | $466.25 | $550.70 | $668.19 | -0.58% |
| November 2026 | $472.95 | $560.54 | $683.88 | +1.79% |
| December 2026 | $470.22 | $559.10 | $685.59 | -0.26% |
Click any year to see its month-by-month UTHR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect UTHR to range from $464.93 to $685.59 through 2026. The $541.58 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The UTHR price prediction for 2027 points to an average of $612.10 (low $501.30, high $781.43) — a potential gain of +13% on today's $541.58. A consolidation phase looks the most probable path here.
In 2028, UTHR is projected to trade between $539.75 and $880.34, averaging $671.43 — a potential gain of +24% from today's $541.58. That is up +10% on the projected 2027 average. Momentum favours further upside here.
United Therapeutics Corporation's 2029 outlook centres on $774.46, within a $613.11 to $1,037.04 range. That is up +15% on the projected 2028 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, UTHR could reach as high as $1,215.37, with a base case around $891.58 and support toward $696.43 — roughly +65% from $541.58. Momentum favours further upside here.
Expect UTHR to range from $812.00 to $1,457.03 through 2031. The $1,052.23 average target implies a +94% move from current prices. That is up +18% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The UTHR price prediction for 2032 points to an average of $1,174.53 (low $896.25, high $1,649.51) — a potential gain of +117% on today's $541.58. Momentum favours further upside here.
In 2033, UTHR is projected to trade between $879.17 and $1,656.29, averaging $1,164.28 — a potential gain of +115% from today's $541.58. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
United Therapeutics Corporation's 2034 outlook centres on $1,265.07, within a $945.87 to $1,821.17 range. That is up +9% on the projected 2033 average. That marks a +134% change versus current levels. Momentum favours further upside here.
By 2035, UTHR could reach as high as $2,028.01, with a base case around $1,393.24 and support toward $1,031.94 — roughly +157% from $541.58. Buyers look set to stay in control over this stretch.
Expect UTHR to range from $1,544.26 to $3,317.09 through 2040. The $2,174.58 average target implies a +302% move from current prices. That is up +56% on the projected 2035 average. Momentum favours further upside here.
The UTHR price prediction for 2050 points to an average of $4,489.17 (low $2,972.47, high $7,340.26) — a potential gain of +729% on today's $541.58. Buyers look set to stay in control over this stretch.
Investing $1,000 in UTHR today (≈ 1.846449 UTHR) could be worth
$8,289.03
+$7,289.03 (+729%) by 2050 · US Dollar
Based on the average projected UTHR price of $4,489.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UTHRwould be worth at today's price.
$1,000 invested in UTHR on Jul 10, 2025 (≈ 3.331556 UTHR) would be worth
$1,804.3
+$804.3 (+80.4%) today · 1.80× · US Dollar
Based on a UTHR entry price of $300.16 vs. today's $541.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $555.91 | $974.22 | -2.6% |
| 1 month ago | $544.1 | $995.37 | -0.5% |
| 3 months ago | $571.73 | $947.27 | -5.3% |
| 6 months ago | $482.39 | $1,122.7 | +12.3% |
| 1 year ago | $300.16 | $1,804.3 | +80.4% |
| All time (5.0y) ago | $185.78 | $2,915.17 | +191.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UTHR forecast.
Our base-case forecast reaches $1,100.00 around 2032.
Implied market cap at $1,100.00: $46.69B
The multi-year forecast paints a strong upside trajectory with clear yearly targets. In 2026, the min is $464.93, the avg is $536.59, and the max is $676.07, with an ROI of 0 and a Neutral sentiment. By 2027, the avg rises to $624.57 with a max of $798.63 and ROI of 16.4.
In 2028, the avg increases to $681.92 with a max of $895.17 and ROI of 27.1, supported by a bullish backdrop. The 2030 forecast shows a min of $725.45, an avg of $929.35, and a max of $1,267.95, with ROI of 73.2 and Bullish sentiment. The trajectory continues with 2031 min $838.43, avg $1,087.14, max $1,506.53 and ROI 102.6; 2032 min $907.02, avg $1,189.30, max $1,671.43 and ROI 121.6; 2033 min $911.10, avg $1,207.20, max $1,718.44 and ROI 125; 2034 min $980.28, avg $1,311.75, max $1,889.49 and ROI 144.5; and 2035 min $1,066.83, avg $1,441.04, max $2,098.75 and ROI 168.6, all with Bullish sentiment.
The forecast then extends to 2040 with min $1,616.96, avg $2,277.88, max $3,476.16 and ROI 324.5, and culminates in 2050 with min $3,094.30, avg $4,674.72, max $7,646.01 and ROI 771.2, continuing the Bullish stance. These figures are estimates, not guarantees, and reflect potential upside given the inputs provided.
Tap a question to reveal the answer.
2030 forecast: min $725.45, avg $929.35, max $1,267.95; ROI 73.2%.
Forecasts show bullish potential over the long term, with rising averages: 2027 avg $624.57 (ROI 16.4%), 2028 avg $681.92 (ROI 27.1%), 2030 avg $929.35 (ROI 73.2%), 2040 avg $2,277.88 (ROI 324.5%), 2050 avg $4,674.72 (ROI 771.2%). These are estimates, not guarantees.
Yes. The 2030 max is $1,267.95 and the 2030 avg is $929.35; other years show higher highs such as 2033 max $1,718.44 and 2034 max $1,889.49.
Current price is $536.59 and market cap is $22.78B.
The 30-day picture is bullish with RSI(14) at 40. The 50-day SMA is $565.40 and the 200-day SMA is $497.47. Near-term support is $536.59 and resistance is $581.74. The 30-day range is $495.37 to $581.24, with annualized volatility of 20%.
United Therapeutics Corporation Community Discussion
0Share your United Therapeutics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.